1. A vaccine composition for transdermal or transmucosal administration for use in the induction of cellular immunity, wherein the vaccine contains: (i) an antigen and (ii) a pharmacologically acceptable acid or its pharmacologically acceptable salt as a first stimulator of induction of cellular immunity. 2. The vaccine composition according to claim 1, characterized in that the composition is intended for use in the treatment of cancer. The vaccine composition according to claim 1, characterized in that the composition is intended for use in the treatment of a viral disease. A vaccine composition according to any one of claims 1 to 3, characterized in that the pharmacologically acceptable acid or its pharmacologically acceptable salt is an organic acid or its pharmacologically acceptable salt. The vaccine composition according to claim 4, characterized in that the organic acid or its pharmacologically acceptable salt is an organic compound having a carboxyl group, or an organic compound having a sulfo group, or a pharmacologically acceptable salt thereof. The vaccine composition according to claim 4, characterized in that the organic acid or its pharmacologically acceptable salt is a saturated or unsaturated, linear or branched fatty acid with a saturated linear component having the number of carbon atoms from 8 to 20, lactic acid, malic acid, salicylic acid acid, maleic acid, citric acid, an organic compound having a sulfo group, or a pharmacologically acceptable salt thereof. 7. The vaccine composition according to claim 4, characterized in that the organic acid or its pharmacologically acceptable salt is1. Композиция вакцины для трансдермального или трансмукозального введения для применения при индукции клеточного иммунитета, причем вакцина содержит:(i) антиген и(ii) фармакологически приемлемую кислоту или ее фармакологически приемлемую соль в качестве первого стимулятора индукции клеточного иммунитета.2. Композиция вакцины по п.1, отличающаяся тем, что композиц
